Last reviewed · How we verify
Decapeptyl Daily
At a glance
| Generic name | Decapeptyl Daily |
|---|---|
| Also known as | Gonapeptyl, Decapeptyl® diario; GnRHa |
| Sponsor | AZ Jan Palfijn Gent |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers (PHASE2, PHASE3)
- Comparison of Sequential CFA vs CFA +rFSH for Elective Fertility Preservation. (PHASE3)
- Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (PHASE3)
- Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (PHASE3)
- Does Recombinant FSH (rFSH, i.g. Gonal F®) as Compared to Human Menopausal Gonadotrophin (hMG) Affect Telomere Length of Cumulus Cells During Antral Follicle Growth and Impact Blastocyst Status?
- Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate (PHASE3)
- GP Extended Action Triptorelin (PHASE4)
- Serum FSH Monitoring for Identification of an Optimal Range During Ovarian Stimulation
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Decapeptyl Daily CI brief — competitive landscape report
- Decapeptyl Daily updates RSS · CI watch RSS
- AZ Jan Palfijn Gent portfolio CI